Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Dechra deals could create animal magic

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Investors are excited by Dechra Pharmaceutical’s (DPH) proposed acquisitions of AST Farma and Le Vet Beheer for a combined €340m announced on 25 January, prompting a 13% share price rally over two days.
Dechra is an international veterinary pharmaceuticals business that derives approximately two-thirds of sales from its companion animal products, essentially medicines for cats and dogs.
We believe the acquisitions are a good strategic fit for Dechra as Le Vet and AST Farma derive approximately 80% of their revenue from companion animal products. The remaining sales are generated equally from treatments for horses, poultry, pigs and cattle.
AST Farma develops generic treatments and sells them directly to vets, while Le Vet sells products through a European network of marketing partners, including Dechra.
The deals are expected to boost underlying earnings per share in the year to 30 June 2018 and be ‘materially accretive’ to earnings in 2019. Investment bank Jefferies reckons they could boost earnings per share by between 11% and 17%.
Jefferies says the €340m price tag implies a multiple of 24.4 times earnings before interest, tax, depreciation and amortisation. The broker expects the price to be ‘far lower’ in reality thanks to the significant growth potential delivered by the deal alongside cost, sales and manufacturing synergies. (LMJ)
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.